Latest news

Thumbnail image for Affimed shares plunge on trial death

Affimed shares plunge on trial death

Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death.

9th October 2018

Thumbnail image for Diurnal shares plummet on trial failure

Diurnal shares plummet on trial failure

Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.

9th October 2018

Thumbnail image for Novartis files MS drug siponimod in EU and US

Novartis files MS drug siponimod in EU and US

Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.

9th October 2018

Thumbnail image for Mixed data for Xencor’s SLE drug

Mixed data for Xencor’s SLE drug

Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.

9th October 2018

Thumbnail image for Four new therapies to be funded by NHS Scotland

Four new therapies to be funded by NHS Scotland

The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.

9th October 2018

Thumbnail image for US nod for Akcea/Ionis’ Tegsedi

US nod for Akcea/Ionis’ Tegsedi

Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.

8th October 2018

Thumbnail image for Demonstrate your skills and expertise

Demonstrate your skills and expertise

The highly anticipated Medical & Scientific Excellence Awards close for entry in just a few weeks (31 October). This is your chance to stand out against the competition, enter now to get the recognition you deserve.

5th October 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download